ClinicalTrials.gg
Active, not recruitingNCT06914908ENSEMBLEUpdated Oct 28, 2026

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

A Phase 2 interventional study of Lunsekimig and Mometasone furoate nasal spray (MFNS) in Chronic Rhinosinusitis With Nasal Polyps, sponsored by Sanofi. Active, not recruiting at 24 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Updated Oct 28, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Nasal Polyps by Sanofi — none open to participants now, 4 under way, 3 of them phase 3. Nasal Polyps · Sanofi.

Enrollment
6th of 12
71 · median 69
Started
2025
with 2 others
Phase 2
4 of 13
none open now
Registered
11th of 13
by date

Among the 13 studies in Nasal Polyps by Sanofi, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2025, is one of 4 in phase 2, and was the 11th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

None of the 13 studies in Nasal Polyps by Sanofi is open now. The open studies under Nasal Polyps, anywhere →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Nasal Polyps by Sanofi as a file.
02

Study summary

This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207).

The study duration will be up to approximately 148 weeks per participant, including 144 weeks of treatment period and 4 weeks of follow-up.

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have completed the treatment period and the follow up period in CRSwNP lunsekimig parent study, including EOS visit, as per protocol
  • Participants receiving therapy with intranasal mometasone furoate nasal spray (MFNS)
  • Participants who are able and willing to participate in this extension study, and to comply with requested study visits and procedures

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Prior reaction to lunsekimig or to any of the used in the presentation or in preparation for administration of lunsekimig, or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
  • Participants who, during their participation in the parent study, developed an adverse event (AE) or a serious adverse event (SAE) deemed related to lunsekimig, which in the opinion of the Investigator could indicate that continued treatment with lunsekimig may present an unreasonable risk for the participant

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Lunsekimig

    Participant will receive lunsekimig subcutaneous (SC) every 4 weeks and intranasal mometasone furoate nasal spray (MFNS) daily for 144 weeks

    Drug: Lunsekimig · Drug: Mometasone furoate nasal spray (MFNS)

Interventions

  • * Pharmaceutical form: solution for injection * Route of administration: subcutaneous

    Also known as: SAR443765

  • * Pharmaceutical form: Solution for administration via spray pump * Route of administration: intranasal spray

06

What researchers measure

Primary outcomes

  1. Incidence of participants with treatment-emergent adverse events (TEAEs) including adverse events of special interest (AESI), and serious adverse events (SAEs)

    Time frame: From baseline to Week 148

Secondary outcomes

  1. Change in Sino-nasal Outcome Test 22 (SNOT-22) total score

    The SNOT-22 is a 22-item health-related outcomes assessment. The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).

    Time frame: From the parent study baseline to Weeks 52, 96 and 144

  2. Change in Rhinosinusitis visual analog scale (VAS)

    The VAS for rhinosinusitis is used to evaluate the total severity. The participant is asked to indicate along a 10 centimeter straight horizontal line (VAS) the answer to the question: "How troublesome are your symptoms of your rhinosinusitis". The VAS ranks from 0 (Not troublesome) to 10 (Worst thinkable troublesome) and is measured in centimeters.

    Time frame: From the parent study baseline to Weeks 52, 96 and 144

  3. Change in The University of Pennsylvania Smell Identification Test (UPSIT) score

    The UPSIT test is a rapid and easy-to-administer method to quantitatively assess human olfactory function. The test consists of four booklets, each containing 10 odorants with one odorant per page. Above each odorant strip is a multiple-choice question with four alternative words to describe the odor. Score depends on the amount of answers out of 40 possible correct answers.

    Time frame: From the parent study baseline to Weeks 52, 96 and 144

  4. Serum lunsekimig concentrations

    Time frame: From baseline to Week 144

  5. Anti-drug antibodies (ADA) against lunsekimig

    Time frame: From baseline to Week 144

07

Study locations

24 sites
  • Orso Health- Site Number : 8400005
    La Jolla, California 92037, United States
  • Capital Allergy & Respiratory Disease Center- Site Number : 8400003
    Roseville, California 95661, United States
  • Treasure Valley Medical Research- Site Number : 8400002
    Boise, Idaho 83706, United States
  • Essential Medical Research- Site Number : 8400020
    Tulsa, Oklahoma 74137, United States
  • Pharmaceutical Research & Consulting- Site Number : 8400004
    Dallas, Texas 75231, United States
  • The University of Texas Health Science Center- Site Number : 8400017
    Houston, Texas 77030, United States
  • ENT Associates of Texas - McKinney- Site Number : 8400014
    McKinney, Texas 75070, United States
  • Alamo ENT Associates- Site Number : 8400001
    San Antonio, Texas 78258, United States
  • Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400008
    Norfolk, Virginia 23510, United States
  • Investigational Site Number : 0320002
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1121, Argentina
  • Investigational Site Number : 0320003
    Mendoza, 5500, Argentina
  • Investigational Site Number : 0560002
    Ghent, 9000, Belgium
  • Investigational Site Number : 0560001
    Leuven, 3000, Belgium
  • Investigational Site Number : 1000001
    Sofia, 1612, Bulgaria
  • Investigational Site Number : 6160004
    Poznan, Greater Poland Voivodeship 60-693, Poland
  • Investigational Site Number : 6160002
    Krakow, Lesser Poland Voivodeship 30-033, Poland
  • Investigational Site Number : 6160007
    Wroclaw, Lower Silesian Voivodeship 53-034, Poland
  • Investigational Site Number : 6160001
    Warsaw, Masovian Voivodeship 00-909, Poland
  • Investigational Site Number : 6160005
    Warsaw, Masovian Voivodeship 02-507, Poland
  • Investigational Site Number : 6160003
    Katowice, Silesian Voivodeship 40-611, Poland
  • Investigational Site Number : 8260004
    Gloucester, Gloucestershire GL1 3NN, United Kingdom
  • Investigational Site Number : 8260003
    Manchester, M13 9wl, United Kingdom
  • Investigational Site Number : 8260001
    Newcastle upon Tyne, NE7 7DN, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Feb 2029, 45 months after the start.

Of 24 phase 2 interventional studies under Nasal Polyps, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 32. This study's planned 45 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Jan 2031 → Feb 2029 and completion Jan 2031 → Feb 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2025
First posted
Apr 7, 2025
StartActual
May 12, 2025
Primary completionEst.
Feb 22, 2029was Jan 2031
CompletionEst.
Feb 22, 2029was Jan 2031
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Active, not recruiting
changed Oct 28, 2026
Sites
4 sites added, 4 sites removed
Show 4 added (4 United States)
  • Orso Health- Site Number : 8400005 · La Jolla, United States
  • Capital Allergy & Respiratory Disease Center- Site Number : 8400003 · Roseville, United States
  • The University of Texas Health Science Center- Site Number : 8400017 · Houston, United States
  • ENT Associates of Texas - McKinney- Site Number : 8400014 · McKinney, United States
Show 4 removed
  • Modena Allergy + Asthma- Site Number : 8400005 · La Jolla, United States
  • Sacramento Ear Nose & Throat - Roseville- Site Number : 8400003 · Roseville, United States
  • McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8400017 · Bellaire, United States
  • ENT Associates of Texas - McKinne- Site Number : 8400014 · McKinney, United States
Oct 13, 2026
Primary completion
Jan 29, 2031→Feb 22, 2029
Oct 28, 2026
Study completion
Jan 29, 2031→Feb 22, 2029
Oct 28, 2026
Show all 2 updates
  1. Oct 28, 2026
    Enrolling by invitation→Active, not recruiting
    Primary completion Jan 29, 2031→Feb 22, 2029
    Study completion Jan 29, 2031→Feb 22, 2029
    + 1 other change: references
  2. Oct 13, 2026
    4 sites added, 4 sites removed
    Show 4 added (4 United States)
    • Orso Health- Site Number : 8400005 · La Jolla, United States
    • Capital Allergy & Respiratory Disease Center- Site Number : 8400003 · Roseville, United States
    • The University of Texas Health Science Center- Site Number : 8400017 · Houston, United States
    • ENT Associates of Texas - McKinney- Site Number : 8400014 · McKinney, United States
    Show 4 removed
    • Modena Allergy + Asthma- Site Number : 8400005 · La Jolla, United States
    • Sacramento Ear Nose & Throat - Roseville- Site Number : 8400003 · Roseville, United States
    • McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8400017 · Bellaire, United States
    • ENT Associates of Texas - McKinne- Site Number : 8400014 · McKinney, United States
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06914908
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 7, 2025
Start date
May 12, 2025
Primary completion
Feb 22, 2029 (estimated)
Completion
Feb 22, 2029 (estimated)
Last update
Oct 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lunsekimig

Start the discussion